

Decoding the Conformational Binding of Drug Mixtures on Ovalbumin: An Integrated Multimodal Network

Michael González-Durruthy^{1,2,*}, Ramón Rial¹, Juan M. Ruso¹

¹Soft Matter and Molecular Biophysics Group, Department of Applied Physics and Institute of Materials (iMATUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.

²NanoSafety Group, International Iberian Nanotechnology Laboratory, Braga, 4715-330, Portugal. (M.G-D currently belongs to NanoSafety Group).

*Corresponding author

E-mail address: gonzalezdurruthy.furg@gmail.com and michael.gonzalez-durruthy@inl.int

Abstract

This research addresses the crucial necessity for a deeper understanding of the binding interactions between surfactants and proteins, with a specific focus on ovalbumin. Considering ovalbumin's role in diverse biochemical processes, it remains a subject of significant interest for drug discovery and design. To fill existing knowledge gaps, we investigated the binding interaction between dicloxacillin and cetyltrimethylammonium bromide (CTAB) on ovalbumin, employing a comprehensive approach that combines computational modeling with experimental validations. Using the ezPocket tool, the computational phase predicted ten relevant binding sites on ovalbumin's surface. The isobologram combination index (CI) heatmap strongly suggested a complex interplay of antagonistic and synergistic effects. Besides, a conformational drug-drug interaction network was proposed to explore the stability of the surfactant mixture within specific binding sites of ovalbumin, revealing a dynamic landscape of suggested antagonist effects. Experimental validations through UV-vis, Fluorescence, and circular dichroism (CD) spectroscopy further corroborated the computational findings, confirming the formation of stable complexes. Finally, this study not only advances our comprehension of ovalbumin's interactions with surfactants but also offers a multidimensional perspective and an advanced methodological framework for efficient therapeutic strategies, opening new avenues for future applications in drug development and applied biochemistry.

33 **Keywords:** Ovalbumin, surfactant mixtures, molecular docking, conformational
34 networks, spectrofluorimetric methods.

35

36 **Highlights:**

- 37 • Structure-based docking on surfactant mixture interactions.
- 38 • Building conformational binding network.
- 39 • Performed mechanistic isobolograms based combination index.
- 40 • Experimental spectrofluorimetric validation.

41

42 **1. Introduction:**

43 Proteins are key biomolecules with crucial roles in biological processes.
44 Understanding their structure and interactions, especially in aqueous environments with
45 molecules like surfactants, is essential for developing new therapeutic strategies. This
46 knowledge is decisive for applications such as drug delivery, protein stabilization, and
47 formulation development [1-3].

48 While protein-surfactant interactions have gained significant attention, the
49 interactions involving protein-surfactant mixtures have been somewhat overlooked.
50 Maldonado-Valderrama conducted thorough research on the interfacial characteristics of
51 these mixtures, shedding light on their impact on interfacial tension, viscoelasticity,
52 surface properties, and foam stability [4, 5]. Miller et al also delved into this area,
53 specifically exploring ionic interactions and the influence of the isoelectric point. In this
54 sense, they developed relevant theoretical models rooted in thermodynamics and
55 statistical mechanics, capable of replicating experimental findings [6, 7].

56 On the other hand, pioneering papers explored the solubilization of solid protein-
57 surfactant complex salts using a second surfactant in order to explore bulk properties of
58 these systems, addressing the predominant influence of the cationic associations over
59 protein-surfactant interactions [8]. Another interesting study investigated the phase
60 behavior in aqueous two-phase systems with cationic-anionic surfactant mixtures,
61 highlighting the role of surfactant ratios, electrostatic interactions and providing
62 molecular insights into protein partitioning, contributing to our understanding of phase
63 separation mechanisms [9], or to discern the effect of the substitution of hydrogen atoms
64 for fluorine atoms [10]. Also noteworthy is the method developed to create magnetic
65 carbon nanotubes (MCNTs) that can bind and stabilize DNA and proteins using cationic
66 surfactants to enhance the electrostatic interaction between biomolecules and MCNTs,
67 facilitating their rapid migration and compaction [11].

68 Within this research domain, ovalbumin (OVA), a major component of egg whites,
69 emerges as a captivating protein because of its high content on essential amino acids
70 which confer unique attributes beyond offering vital antimicrobial protection to the
71 developing embryo [12, 13]. Ovalbumin has a primary structure consisting of a single
72 polypeptide chain containing approximately 385 amino acid residues, with a molecular
73 weight ranging from 45-50 kDa. Its secondary structure mainly adopts a α -helical
74 conformation, with α -helices contributing approximately 60% of the secondary structure,
75 thereby enhancing stability. Additionally, ovalbumin contains 1 disulfide bond that

76 enhance its stability by creating covalent linkages between specific cysteine residues
77 (Cys87 and Cys133) within the polypeptide chain A [14, 15]. The ovalbumin's tertiary
78 structure assumes a compact globular shape, which is stabilized by various non-covalent
79 interactions, including hydrogen bonds, hydrophobic interactions, and van der Waals
80 forces. Regarding all the points mentioned above, the physicochemical properties of
81 ovalbumin have captured the interest of the scientific community, particularly in the
82 context of interaction studies (including surfactant-drug mixtures studies), sparking
83 curiosity among researchers in various scientific fields as food industry, biotechnology,
84 pharmaceuticals, and drug development [16].

85 In this scenario, dicloxacillin (diclox) and CTAB are well-known surfactants that
86 exhibit distinct characteristics and have been extensively studied individually.
87 Dicloxacillin is a β -lactam penicillin-derivative well-known for its strong antibiotic
88 properties, commonly used to treat infections caused by Gram-positive bacteria due to its
89 ability to disrupt bacterial cell wall synthesis. While it is typically classified as a
90 therapeutic drug or pharmacological agent, its amphiphilic nature has sparked interest in
91 its potential surface-active properties from a purely chemical perspective [17]. On the
92 other hand, cetyltrimethylammonium bromide (CTAB) is a versatile compound with
93 diverse applications. From a chemical standpoint, CTAB is classified as a cationic
94 surfactant, demonstrating a strong affinity for negatively charged groups from
95 biomolecules, including proteins such as ovalbumin. Its high capacity to form micelles
96 and interact with lipid membranes has led to its utilization in drug delivery and gene
97 therapy [16]. Additionally, CTAB has been widely used in cosmetics and personal care
98 products due to its emulsifying and conditioning effects. In molecular biology, CTAB is
99 essential for DNA extraction, aiding in the separation of DNA from proteins and other
100 cellular components. Furthermore, CTAB plays a pivotal role in material science, acting
101 as a stabilizing agent in the synthesis of nanoparticles and nanomaterials to prevent
102 particle aggregation. In the field of chemistry, CTAB serves as a cationic surfactant in
103 various reactions, solubilizing a broad range of compounds in its micellar structures. This
104 property facilitates chemical reactions and promotes the formation of organized
105 assemblies, making CTAB valuable for applications such as thin film synthesis,
106 nanomaterial templates, and the preparation of functional materials [18].

107 To study the interactions between ovalbumin and the dicloxacillin-CTAB mixture,
108 a combined approach involving experimental techniques and heuristic computational
109 methods was employed. This integration of experimental and computational approaches

110 presents several advantages. Primarily, it allows for the validation and cross-verification
111 of the information obtained from both sources, thereby improving the reliability of the
112 results. Secondly, it offers a multi-scale viewpoint, allowing the examination of both
113 macroscopic characteristics and microscopic details concurrently. Among the
114 experimental methods, ultraviolet-visible (UV-Vis) and fluorescence spectrometry have
115 gained substantial prominence due to their adaptability, precision, and non-invasive
116 properties in revealing the complexities of protein-surfactant interactions and
117 highlighting the dynamic exchange between the molecules. Through integrating
118 spectroscopic approaches, one can gain new insights into the structural, thermodynamic,
119 and kinetic aspects of interactions between proteins and surfactants [19]. In recent years,
120 computational techniques have become essential in elucidating complex interactions.
121 Two techniques that have gained special attention are molecular docking simulations and
122 Combination Index (CI) methodology, which can explore the binding mechanisms and
123 thermodynamics of protein-surfactant as complex mixture [20]. With molecular docking
124 simulations, one can predict the modes and strengths of protein-surfactant interactions
125 [21]. Additionally, the CI methodology was employed to analyze the interaction between
126 ovalbumin and the surfactant mixture. Our novel approach offers a strong theoretical and
127 computational framework to determine whether these interactions are synergistic,
128 additive, or antagonistic [20, 22-26]. We focus on the computational modeling aspects of
129 our methodology to accurately quantify the subtle dynamics between the protein and the
130 surfactant mixture. The use of theoretical isobolograms is essential to our analysis as they
131 offer a graphical representation of the interaction patterns [20, 22-26].

132 This study could significantly contribute to boosting the knowledge of molecular
133 interactions in such systems and makes a significant contribution to the field of surfactant-
134 protein interactions. This understanding will aid in creating precise conformational
135 models and theories about the behavior of ovalbumin in the presence of the dicloxacillin-
136 CTAB mixture, advancing progress in drug design, biotechnological applications, and
137 tailored surfactant development.

138

139 **2. Materials and Methods.**

140 **2.1. Computational Approach.**

141 **2.1.1. Binding pockets predictions**

142 Utilizing the ezPocket software, ten binding site cavities of the ovalbumin receptor
143 (RCSB PDB ID: 1OVA) were well-identified. This software employs an algorithm rooted
144 in Delaunay triangulation with weighted points and rapid Voronoi tessellation to analyze
145 the protein's concave surfaces, pinpointing pertinent binding pockets. The algorithm
146 employs a grid-based methodology to evaluate protein surface attributes, encompassing
147 hydrophobicity, polarity, and morphology. Post-execution, the software yields ranked data
148 on detected junction cavities, the central XYZ coordinates of these cavities, and their
149 respective volumes. Concurrently, a 3D representation of all identified cavities is rendered
150 for visualization. Herein, ten relevant binding sites were obtained as volumetric maps for
151 the ovalbumin receptor allowing to set the specific three-dimensional discrete space as
152 docking box simulations [27, 28] in each pockets as follow: *pocket 1* grid box size with
153 dimensions of $X = 20 \text{ \AA}$, $Y = 20 \text{ \AA}$, $Z = 20 \text{ \AA}$ and grid box center $X = 5.65 \text{ \AA}$, $Y = 49.91$
154 \AA , $Z = 37.56 \text{ \AA}$, with volume equal to 11231.9 \AA^3 ; *pocket 2* grid box size with dimensions
155 of $X = 20 \text{ \AA}$, $Y = 20 \text{ \AA}$, $Z = 20 \text{ \AA}$ and grid box center $X = 13.68 \text{ \AA}$, $Y = 25.64 \text{ \AA}$, $Z = 43.33$
156 \AA , with volume equal to 1555.96 \AA^3 ; *pocket 3* grid box size with dimensions of $X = 20$
157 \AA , $Y = 20 \text{ \AA}$, $Z = 20 \text{ \AA}$ and grid box center $X = -4.06 \text{ \AA}$, $Y = 62.88 \text{ \AA}$, $Z = 40.73 \text{ \AA}$, with
158 volume equal to 1393.71 \AA^3 ; *pocket 4* grid box size with dimensions of $X = 20 \text{ \AA}$, $Y = 20$
159 \AA , $Z = 20 \text{ \AA}$ and grid box center $X = -20.52 \text{ \AA}$, $Y = 71.09 \text{ \AA}$, $Z = 41.15 \text{ \AA}$, with volume
160 equal to 1172.77 \AA^3 ; *pocket 5* grid box size with dimensions of $X = 20 \text{ \AA}$, $Y = 20 \text{ \AA}$, $Z =$
161 20 \AA and grid box center $X = 9.22 \text{ \AA}$, $Y = 19.83 \text{ \AA}$, $Z = 30.54 \text{ \AA}$, with volume equal to
162 887.56 \AA^3 ; *pocket 6* grid box size with dimensions of $X = 20 \text{ \AA}$, $Y = 20 \text{ \AA}$, $Z = 20 \text{ \AA}$ and
163 grid box center $X = -22.32 \text{ \AA}$, $Y = 55.94 \text{ \AA}$, $Z = 57.16 \text{ \AA}$, with volume equal to 625.11
164 \AA^3 ; *pocket 7* grid box size with dimensions of $X = 20 \text{ \AA}$, $Y = 20 \text{ \AA}$, $Z = 20 \text{ \AA}$ and grid box
165 center $X = 31.39 \text{ \AA}$, $Y = 37.65 \text{ \AA}$, $Z = 31.30 \text{ \AA}$, with volume equal to 602.04 \AA^3 ; *pocket*
166 *8* grid box size with dimensions of $X = 20 \text{ \AA}$, $Y = 20 \text{ \AA}$, $Z = 20 \text{ \AA}$ and grid box center X
167 $= -10.30 \text{ \AA}$, $Y = 23.92 \text{ \AA}$, $Z = 30.19 \text{ \AA}$, with volume equal to 525.40 \AA^3 ; *pocket 9* grid box
168 size with dimensions of $X = 20 \text{ \AA}$, $Y = 20 \text{ \AA}$, $Z = 20 \text{ \AA}$ and grid box center $X = -22.15 \text{ \AA}$,
169 $Y = 62.33 \text{ \AA}$, $Z = 31.96 \text{ \AA}$, with volume equal to 508.45 \AA^3 ; *pocket 10* grid box size with
170 dimensions of $X = 20 \text{ \AA}$, $Y = 20 \text{ \AA}$, $Z = 20 \text{ \AA}$ and grid box center $X = 5.87 \text{ \AA}$, $Y = 82.75$
171 \AA , $Z = 43.11 \text{ \AA}$, with volume equal to 493.40 \AA^3 .

172 ***2.1.2. Molecular docking and conformational drug-drug interaction network***

173 A molecular docking approach was executed by using AMDock, a software tailored
174 for proficient prediction of protein-ligand binding modes and ΔG binding affinities
175 (kcal/mol). AMDock's methodology amalgamates a genetic algorithm with a grid-based
176 strategy.[29] The preliminary phase necessitated the preparation of the ovalbumin
177 receptor and the ligand structures of the binary cationic mixture, specifically
178 dicloxacillin (PubChem CID: 18381; MW: 470.3 g/mol) and
179 hexadecyltrimethylammonium bromide-CTAB (PubChem CID: 5974; MW: 364.4
180 g/mol) [30].

181 For the ovalbumin structure, co-crystallized ligands and water molecules were
182 excised. The dicloxacillin and CTAB structures forming the mixture were primed by
183 allocating Gasteiger charges and optimizing geometries. The AMDock algorithm
184 employs a hybrid scoring function, amalgamating various energy force field terms, to
185 assess the ligand's binding affinity across diverse orientations and conformations. For
186 discerning the paramount binding mode based on individual ligand conformations (N =
187 10 conformations) and the binary mixture, AMDock adopts a hierarchical simulation
188 protocol [29]. This commences with a coarse-grained search via an FFT-based technique,
189 succeeded by a refinement phase leveraging a Monte Carlo algorithm. Subsequent to
190 docking, the predicted conformational binding modes and ΔG affinities values undergo
191 further scrutiny and validation through an array of post-docking analytical tools aiming
192 to further construction of the conformational drug-drug interaction network in three
193 simulation conditions i) dicloxacillin conformational drug-drug interaction network, ii)
194 CTAB conformational drug-drug interaction network, and iii) mixture dicloxacillin plus
195 CTAB conformational drug-drug interaction network [29].

196 ***2.1.3. Determining the mixture combination index (CI)***

197 The Combination Index (CI) methodology was introduced to theoretically evaluate
198 the drug combination binding effects (ie., antagonism or synergism) of a cationic
199 mixture formed by CTAB and dicloxacillin under interaction with each of the ten
200 Ovalbumin binding pockets (numbered from $\theta = 1$ to $\theta = 10$) [22, 24-26, 31]. Within this
201 computational framework, the foundational principle posits that two ligands or drugs
202 exhibit synergistic binding affinity when their joint binding effect surpasses the
203 cumulative effect of their individual binding contributions. Conversely, they display
204 antagonistic binding affinity when their combined effect is less to their individual effects.
205

206 To ascertain CI values, it's imperative to assay various theoretical concentrations of each
207 drug, both singularly and in tandem, and subsequently gauge the binding impact of the
208 combination on the respective ovalbumin binding pockets. Given the theoretical docking
209 simulation data, the CI for each catanionic ligand combination can be expressed according
210 to the equation:

$$211$$
$$212 \quad CI_{(CTAB-dicloxacillin)} = \sum_{\theta=1}^{\theta=10} \frac{C_{CTAB}}{C_{i_CTAB}} + \frac{C_{dicloxacillin}}{C_{i_dicloxacillin}} + \frac{C_{CTAB}C_{dicloxacillin}}{C_{i_CTAB}C_{i_dicloxacillin}} \quad (1)$$
$$213$$

214 Here, C_{CTAB} and $C_{dicloxacillin}$ represent the theoretical concentrations of CTAB and
215 dicloxacillin in the catanionic mixture, respectively. Meanwhile, C_{i_CTAB} and $C_{i_dicloxacillin}$
216 denote the theoretical concentrations of CTAB and dicloxacillin that yield an equivalent
217 effect when administered individually. The CI value for the CTAB-dicloxacillin mixture
218 binding combination spans from < 1 to > 1 and can be estimated as the summation of the
219 mixture and individual binding contribution of the ligands (CTAB-dicloxacillin) with the
220 all the pocket binding sites denoted by the parameter θ (i.e., covering from the site $\theta = 1$
221 to $\theta = 10$). From the mechanistic point of view, CI values < 1 can be associated to
222 synergistic binding effect, CI values equal to 1 represent an additive binding effect, while
223 CI values > 1 indicate an antagonistic binding effect. The obtained graph is called as
224 theoretical isobologram representing a 2D matrix of drug-drug binding combination at a
225 given theoretical concentration ranging from 0.0 mM to 1.0 mM. Theoretical
226 isobolograms allow the visualization of the ligand interaction's nature its magnitude under
227 combination conditions, such as in mixtures.

228

229 **2.2. Experimental validation**

230 **2.2.1. Reagents**

231 Hexadecyltrimethylammonium bromide (CTAB, 99%, ref. n. H5882), sodium
232 dicloxacillin [3-(2,6 - dichlorophenyl)-5-methyl-4-Isloxazolyl penicillin] (ref. n.
233 D9016) and ovalbumin (albumin, chicken egg, product A-5253, powder, molecular
234 weight 44287 Da, 62-88% agarose gel electrophoresis, Sigma Chemical Company)
235 were used without further purification. Samples were freshly prepared for each
236 experiment within 1 h. prior to usage. Solutions were made using triple-distilled and
237 degassed water.

238

239

240 **2.2.2. UV-vis absorption spectra**

241 UV-visible absorption spectra were obtained using a Cary 100 Bio UV-Vis
242 Spectrophotometer within a wavelength range of 225 – 400 nm. A standard solution of
243 ovalbumin, at a concentration of 1 mg/mL (equivalent to 0.07 mM), served as the
244 reference for UV measurements. To assess the individual absorbance effects of each
245 compound, solutions of pure dicloxacillin and CTAB were incrementally introduced in
246 concentrations between 0.083 mM and 0.83 mM, ensuring a consistent ovalbumin
247 concentration. According to the literature, the peak plasma concentration of dicloxacillin
248 in standard dosage can reach up 0.2 mM [32]. Additionally, we aimed to investigate the
249 impact of reaching the critical micelle concentration of CTAB, documented to be between
250 0.8 - 0.9 mM [33]. Hence, concentration interval was selected to align with both the
251 plasma drug concentration range and the CMC of CTAB. Additionally, mixtures with
252 equal concentrations of both ligands were introduced to the 0.07 mM protein solution.
253 Each measurement was conducted in duplicate to validate accuracy and reduce potential
254 errors. The observed replicates exhibited negligible variation, with the reported data
255 reflecting the average of both measurements.

256

257 **2.2.3. Fluorescence emission spectra**

258 Fluorescence emission spectra were obtained using a Cary Eclipse
259 spectrofluorometer, with both excitation and emission slits calibrated to 5 nm.
260 Measurements were taken at 0.5 nm intervals, averaging over a 0.5 s duration. The
261 excitation was consistently set at 280 nm, and the spectral analysis spanned from 250–
262 550 nm. To account for inner filter effects and ensure accurate quenching results,
263 corrections were applied using the formula: $F_{\text{corr}} = F_{\text{obs}} \times 10^{[(A_{\text{exc}}+A_{\text{em}})/2]}$, where F_{corr}
264 and F_{obs} denote the corrected and observed fluorescence intensities, respectively. A_{exc}
265 and A_{em} represent the system's absorptions at the excitation and emission wavelengths,
266 respectively. Data analysis was facilitated by the UV-Vis-IR Spectral Software
267 (FluorTools) [34]. The fluorescence spectra of the Ovalbumin-cationic compound
268 complexes were examined in a manner analogous to the UV-vis approach. Initially, each
269 ligand was added individually, followed by the combined cationic mixture.
270 Concentrations for these measurements varied between 0.083 mM and 0.83 mM.

271

272 **2.2.4. Circular Dichroism (CD)**


273 Utilizing a JASCO-715 spectropolarimeter (Japan) equipped with a JASCO PTC-
274 343 Peltier-regulated cell holder, Far-UV circular dichroism (CD) spectra were procured.
275 For spectral acquisition, quartz cuvettes possessing a pathlength of precisely 0.2 cm were
276 employed. The spectral range was recorder between 190 and 280 nm for both pure protein
277 and ligand solutions. The protein sample was 1 mg/mL, corresponding to a molarity of
278 0.02 mM. Concurrently, a mixture of dicloxacillin and CTAB was added, with
279 concentrations ranged from 0.83 to 4.2 mM for both compounds. Instrumental parameters
280 were meticulously set: a resolution and bandwidth both at 1 nm, sensitivity calibrated at
281 50 mdeg, a response interval of 8 s, an accumulation factor of 3, and a scanning velocity
282 of 50 nm/min. Any absorbance attributable to doubly distilled water was methodically
283 negated, adhering to the instrumental parameters. Experimental data were expressed in
284 terms of molar ellipticity by the equation $[\theta]_{\lambda} = \theta_{\lambda}M_r/ncl$, where M_r is the molecular
285 weight of the protein, n represents residue quantity, c is the protein concentration, l
286 corresponds to the cuvette's path length, and θ_{λ} is the ellipticity at a wavelength λ given
287 by the apparatus. The resultant CD profiles represent the composite spectra inherent to α -
288 helix, β -sheet, β -turn, and random coil configurations. Subsequent analysis of secondary
289 structure composition was conducted using the webserver BeStSel software [35].

291 **3. Results and discussion**

292 **3.1 Computational approaches**

293 **3.1.1 Binding site prediction and structural characterization**

294 Predicting binding sites is generally a complex and challenging task, with different
295 strategies and methods being suitable depending on the specific target molecule and
296 applications. In this context, we used the ezPocket tool to computationally predict and
297 identify potential binding sites on the ovalbumin as receptor, which resulted in ten
298 potential binding pockets spread across the ovalbumin's surface. To this end, the ezPocket
299 tool was applied which has been systematically used and validated in the context of
300 multiple modeling problems [28, 36]. It works by identifying concave cavities that could
301 potentially bind ligands (such as CTAB and dicloxacillin) and excluding convex ones in
302 the protein structure, considering the ovalbumin's shape and size, as shown in **Figure 1**.



304

305 **Figure 1.** On the top, from panel **A)** to panel **J)**, is depicted the whole crystallographic 3D-structure of the
 306 ovalbumin with the predicted binding sites (from site $\theta=1$ to $\theta=10$) spread across the ovalbumin's surface
 307 as van der Waals volumetric surface labelled-cyan. In the bottom is represented a breakdown of the four
 308 ovalbumin's constitutional chains as **K)** chain A (labelled-red), **L)** chain B (labelled-yellow), **M)** chain C
 309 (labelled-light blue), and **N)** chain D (labelled-dark blue).

310 The **Figure 1** results on the binding sites prediction allow us to understanding the
 311 topological characteristics and size of the binding pockets in the ovalbumin which is
 312 crucial for understanding both, its function, and potential applications in structure-based
 313 drug design. Herein, the identified binding sites and their intrinsic structural differences
 314 (i.e., the constitutional chains A, B, C, D determining the pocket dimensions $\text{Vol}(\text{\AA}^3)$)
 315 (please, refer to **Materials and methods section 2.1.1**) will further determine the
 316 stability-based binding affinity, type and strengths of interactions with the evaluated
 317 molecules (CTAB and dicloxacillin) will bind and undergo a chemical reaction under
 318 mixture combination [28, 36]. These sites are typically pockets or grooves on the
 319 ovalbumin's surface that could fit the physiological substrates both in shape and in the
 320 chemical characteristics and could be directly affected by the interaction of the ligands
 321 dicloxacillin and CTAB by separated, or by the interaction with the mixture (i.e., CTAB
 322 plus dicloxacillin). Then, knowing the properties of these ten predicted binding sites
 323 (from site 1 to site 10) associated with the cited structural chains that form part of each of
 324 them, allows us to understand the ligand specificity by the ovalbumin protein, its binding
 325 mechanism, and theoretically explain potential binding perturbations which will be
 326 addressed in detail in the following sections.


327 In the binding mixture scenario, the study of docking interactions of ligands (as CTAB
328 plus dicloxacillin) holds significant relevance. Then, CTAB and dicloxacillin could act
329 by interacting with the binding sites of the ovalbumin, either amplifying or inhibiting the
330 protein's activity. The combination of CTAB and dicloxacillin could interact with the
331 active sites in unique ways, potentially leading to a range of effects. This could result in
332 synergistic binding effects, where the combined impact of the CTAB and dicloxacillin
333 ligands is greater than the sum of their individual effects. Alternatively, it could lead to
334 antagonism or competitive inhibition, where the cited mixture of ligands competes for the
335 same binding site in the ovalbumin. Further explanation will be provided later.

336

337 *3.1.2 Computational modelling on the mixture binding affinity*

338 In the following discussion, we will examine the relationship between key factors to
339 theoretically elucidate the effect of the mixture on its interaction with ovalbumin. We
340 have employed several approaches to achieve this, including: i) assessing the
341 thermodynamic binding affinity (ΔG , kcal/mol) in relation to the frequency of binding,
342 ii) constructing a comprehensive isobologram combination index (CI) heatmap to
343 understand the binding mechanism of the mixture as either antagonistic or synergistic,
344 with theoretical concentrations obtained after docking simulation, and iii) conducting a
345 site-specific and global evaluation of the fractional binding occupancy in relation to the
346 combination index of the mixture. Please refer to **Figure 2** for a visual representation.

347



348

349 **Figure 2. A)** Graphical representation of the overall docking results showing the relationship between the
 350 binding affinity ΔG (kcal/mol) vs. frequency of binding by considering the three main ligand interaction
 351 evaluated in this study as CTAB (labelled-blue bars), dicloxacillin (labelled-pink bars), and the mixture
 352 CTAB plus dicloxacillin (labelled-dark red bars) for the whole structure of ovalbumin. **B)** Graphical
 353 representation of the theoretical 2D-isobolograms between CTAB and dicloxacillin under mixture binding
 354 combination in the whole lysozyme. Herein, the intensity bar color in the right-side of the heatmap is to
 355 represent the combination index (CI) of the evaluated mixture where labeled-red region ($CI_{(CTAB-Dicloxacillin)}$
 356 > 1) corresponds to antagonistic binding effects. While labeled-blue region ($CI_{(CTAB-Dicloxacillin)} < 1$)
 357 corresponds to synergistic binding effects, red and blue circles scattered in the heatmap represent the
 358 different conformations for both ligand CTAB and dicloxacillin; respectively. **C)** Graphical representation
 359 of the relationship between the fractional occupancy vs. combination index of the mixture in an antagonism
 360 scenario ($CI > 1$) showing a decrease in antagonistic behavior ($CI > 1$) with increasing fractional occupancy
 361 for individual site-specific and global interactions with the protein. Also, the values for the dissociation
 362 constants of the mixture (K_{d_mix}) in each binding site (θ ; form the site $\theta = 1$ to $\theta = 10$) are represented.

363

364 First, we will begin by examining the thermodynamic binding affinity results to gain an
 365 understanding of the interaction strength between the ligands (CTAB and dicloxacillin)
 366 and the active sites of ovalbumin. A lower ΔG value (kcal/mol) indicates a more
 367 favourable interaction, which can be linked to a higher frequency of binding. Regarding
 368 the **Figure 2** panel **A)**, we can note that the ΔG affinity values of the CTAB and
 369 dicloxacillin mixture range from -6.9 kcal/mol to -4.4 kcal/mol. It's also noticeable that
 370 the binding frequency of CTAB is two times higher (10^2) than the binding frequency (10)

371 of the dicloxacillin within the same affinity range. However, theoretically, the strength of
372 the interactions for CTAB appear to be lower compared to dicloxacillin, based on the
373 lowest binding affinity value of CTAB ($\Delta G = -3$ kcal/mol) compared with the lowest
374 affinity observed for dicloxacillin ($\Delta G = -3.7$ kcal/mol). This suggests that while CTAB
375 may bind more often with the ovalbumin binding sites, the interactions it forms are less
376 energetically favourable compared to those formed by dicloxacillin.

377 This differential binding behaviour could have significant implications for the function
378 of the ovalbumin protein. Because proteins work by binding to their physiological
379 substrates at their active sites and facilitating biochemical reactions, the strength of this
380 binding, as indicated by the binding affinity, could theoretically influence the rate and
381 efficiency of these biochemical reactions and the overall function of the ovalbumin
382 protein. Secondly, from the mechanistic point of view, the isobologram combination
383 index (CI) heatmap allows us to visualize the binding mechanism of the CTAB plus
384 dicloxacillin mixture [20, 22-26]. By examining the heatmap, we can determine whether
385 the evaluated ligands in the mixture bind to the ovalbumin protein in a synergistic or
386 antagonistic manner. Besides, the binding affinity observed in the interaction between the
387 CTAB and dicloxacillin mixture with ovalbumin could be significantly influenced by
388 several factors. These include: i) the obtained theoretical concentration range of the
389 CTAB and dicloxacillin mixture being evaluated, ii) the combination index (CI) of the
390 mixture, and iii) the unique amino-acid chain composition and molecular structure of the
391 different ovalbumin binding pockets evaluated (refer to **Figure 1**). It's conceivable that
392 mechanisms based on synergistic binding effects could coexist with antagonistic binding
393 effects within the same ovalbumin pocket [20, 22-26]. This can be effectively studied by
394 determining the CI by performing the whole isobologram considering that it includes all
395 the binding pockets (i.e., covering from the site $\theta = 1$ to $\theta = 10$). See **Figure 2** panel **B**.

396 For this instance, we could theoretically suggest the presence of both binding behaviours
397 (i.e., antagonistic > synergistic ~ additive binding effect) for the cationic mixture
398 interacting with the protein. As shown in **Figure 2B**, the red-labelled region of the
399 isobologram with CI (CTAB-dicloxacillin) > 1 represents antagonistic binding effects
400 while the blue-labelled one with CI (CTAB-dicloxacillin) < 1 represents synergistic
401 binding effects. Then, it is clear a predominance of antagonistic binding effects for the
402 whole protein in the range of theoretical concentration from 0.1 mM to 1 mM for
403 dicloxacillin and from 0.1 mM to 0.25 mM for the CTAB. Regarding the tendency to
404 induce synergistic binding for the case of dicloxacillin appears in the range of theoretical

405 docking concentration from 0.1 mM to 0.2 mM while in the case of CTAB appears in the
406 concentration interval from 0.4 mM to 1 mM. The additive effects ($CI = 1$) seem to have
407 less relevance in the context of this study.

408 Lastly, the evaluation of the fractional binding occupancy in relation to the combination
409 index of the mixture provides a comprehensive view of how the ligands in the mixture
410 interact with the protein's active sites. This could help to understand how the mixture as
411 a whole system affects the function of the ovalbumin protein [37, 38].

412 According to the results obtained in the **Figure 2C**. In the context of the relationship
413 between the fractional occupancy vs. combination index (CI) graph, a global and
414 individual decrease within an antagonistic scenario ($CI > 1$). Could increase the fractional
415 occupancy as showed. This fact suggests that, as more binding sites on the ovalbumin are
416 occupied by the ligands in the mixture, the overall interaction becomes less antagonistic.
417 This could be attributed to various factors, such as changes in the binding site
418 conformation or the influence of different CTAB and/or dicloxacillin binding
419 conformations linked to alterations in the local biophysical environment at the binding
420 sites [37, 38].


421 From a biochemical perspective, this shift from antagonism to less antagonistic or even
422 potentially synergistic interactions could have significant implications. It could alter the
423 rate and efficiency of the reactions catalysed by the ovalbumin protein, potentially
424 affecting catalytic pathways in which ovalbumin is involved. Regarding the dissociation
425 constants of the mixture (as Kd_{mix}) in each binding site of the ovalbumin provided
426 valuable insights into the binding affinities of the CTAB and dicloxacillin mixture with
427 ovalbumin. Lower Kd values indicate stronger binding affinities, suggesting that binding
428 sites 3 and 10 have the strongest interactions with the mixture, while binding sites 8 and
429 7 have the weakest. This differential binding affinity could theoretically could modules
430 the activity of the ovalbumin when separately evaluated [37-40].

431

432 ***3.1.3 Results on conformational drug-drug interaction network on ovalbumin***


433 In the context of this mechanistic study, it is essential to address not only the drug-drug
434 interactions within the entire mixture formed by the CTAB and dicloxacillin system but
435 also interactions that may occur individually, such as CTAB with CTAB or dicloxacillin
436 with dicloxacillin in a drug-drug interaction system. The complexity of the issue

437 intensifies when we simulate the influence of various conformations interacting with
 438 different binding sites of the protein [41-44].
 439 Understanding the conformational drug-drug interaction network requires us to consider
 440 the intricate interplay between different ligands within the mixture and how these
 441 interactions could vary depending on the specific binding sites on the ovalbumin protein.
 442 This comprehensive exploration is essential to understand the interdependent
 443 conformational network of synergistic or antagonistic effects on the structure, dynamics,
 444 and interactions of ovalbumin, which may have significant implications for its
 445 biochemical function. To address the high-dimensionality of this conformational network
 446 problem, mechanistic results and corresponding interpretations will be provided for both
 447 the best- and worst-ranked binding sites of ovalbumin based on the stability of the formed
 448 docking complexes. See **Figure 3**.



449
 450 **Figure 3.** **A)** Representation of the conformational drug-drug interaction network within the same category
 451 (dicloxacillin plus dicloxacillin) showing the conformational network architecture resulting from the
 452 docking interactions with the different binding sites of the ovalbumin (covering from the site $\theta = 1$ to $\theta = 10$).
 453 Herein, the associated colour intensity bar (from blue to red) in the right-side of the network is to represent
 454 the strength of the interactions-based affinity (kcal/mol). Being the x-axis the i -conformation (dicloxacillin)
 455 vs. the y-axis as the specific j -binding site evaluated. **B)** Representation of the best-ranked binding site of
 456 the ovalbumin (site 10, chains C and D) showing the best interaction stability of the docking complexes for
 457 the dicloxacillin plus dicloxacillin system (network nodes mainly labelled-yellow to red). **C)**
 458 Representation of the worst-ranked binding site of the ovalbumin (site 4, chains C and D) showing the
 459 worst interaction stability of the docking complexes for the dicloxacillin plus dicloxacillin system (network

460 nodes mainly labelled-grey to light green) that means lower docking stability in the binding site 4 (just two
461 dicloxacillin poses were detected).



462
463 **Figure 4.** A) Representation of the conformational drug-drug interaction network within the same category
464 (CTAB plus CTAB) showing the conformational network architecture resulting from the docking
465 interactions with the different binding sites of the ovalbumin (covering from the site $\theta=1$ to $\theta=10$). Herein,
466 the associated colour intensity bar (from blue to red) in the right-side of the network is to represents the
467 strength of the interactions-based affinity (kcal/mol). Being the x-axis the i -conformation (CTAB) vs. the
468 y-axis as the specific j -binding site evaluated. B) Representation of the best-ranked binding site of the
469 ovalbumin (site 2, chains A and B) showing the best interaction stability of the docking complexes for the
470 CTAB plus CTAB system (network nodes mainly labelled-blue to green). C) Representation of the worst-
471 ranked binding site of the ovalbumin (site 9, chains C and D) showing the worst interaction stability of the
472 docking complexes for the CTAB plus CTAB system (network nodes mainly labelled light blue to dark
473 blue) that means lower docking stability in the binding site 9 (just four CTAB poses were detected).


474
475 In both drug-drug interaction networks, involving the same category as i) dicloxacillin
476 plus dicloxacillin and ii) CTAB plus CTAB, a mechanistic and molecular docking
477 analysis was performed to elucidate their conformational architectures within the context
478 of different ovalbumin binding sites. The obtained conformational networks allow us to
479 illustrate the conformational landscape resulting from docking interaction affinity across
480 the different binding sites evaluated ($\theta=1$ to $\theta=10$). In the dicloxacillin system, the best-
481 ranked binding site (site 10) exhibited high interaction stability, indicated by
482 predominantly yellow to red network nodes, while the worst-ranked binding site (site 4)

483 displayed lower stability, shown as primarily grey to light green nodes. Similarly, in the
484 CTAB system, the best-ranked binding site (site 2) demonstrated strong interaction
485 stability (blue to green nodes), whereas the worst-ranked binding site (site 9) exhibited
486 lower stability, shown with light blue to dark blue nodes.

487 Regarding the two conformational drug-drug interaction networks obtained for the
488 isolated systems (i.e., pure or without the mixture) represented by as: i) conformational
489 network of dicloxacillin-dicloxacillin interaction (**Figure 3A**) and ii) conformational
490 network of CTAB-CTAB interaction (**Figure 4A**). It is clear to note that, the obtained
491 values of the interaction affinity (kcal/mol) for the conformational dicloxacillin-
492 dicloxacillin network interacting system exhibits significantly higher affinity values (in
493 the range from -5.5 kcal/mol to -7.0 kcal/mol) compared with the conformational CTAB-
494 CTAB network interacting systems (in the range from -4.0 kcal/mol to -5.0 kcal/mol).
495 This theoretical insight is strongly associated with a higher strength of interactions for
496 dicloxacillin-dicloxacillin drug-drug system respect to the CTAB-CTAB which was
497 expressed in overall ovalbumin binding site evaluated. It is well-known that, from a
498 thermodynamic-based interaction stability point of view, a more negative values of the
499 Gibbs free energy ΔG (kcal/mol) indicates the formation of more stable docking
500 complexes (i.e., dicloxacillin-dicloxacillin plus OVA \gg CTAB-CTAB plus OVA).
501 Except for the network nodes dicloxacillin-dicloxacillin which include the conformations
502 3, 4, 5, 6, 8 and 10 of the dicloxacillin-dicloxacillin drug-drug system placed within the
503 binding site $\theta = 4$, where energetically unfavorable dicloxacillin-dicloxacillin plus OVA
504 docking complexes were obtained. Suggesting either an extremely low or complete
505 absence of binding affinity maybe by the presence of repulsive interactions in this specific
506 biophysical environment ($\theta = 4$) nodes-labelled as gray).

507 The consideration of drug-drug interactions within the same category (i.e., CTAB plus
508 CTAB and dicloxacillin plus dicloxacillin) is an imperative to discern how these
509 interactions may contribute independently to the overall conformational landscape of the
510 ovalbumin protein. The conformational drug-drug interaction network under
511 investigation not only involves the interactions within the mixture but also the study of
512 interactions occurring individually. The simultaneous exploration of these aspects
513 provides a more comprehensive understanding of the intricate mechanisms at play,
514 particularly when considering the diverse conformations interacting with various binding
515 sites of the ovalbumin. These theoretical findings collectively emphasize the significance
516 of understanding the specific binding sites and their corresponding interaction stabilities

517 alone as a starting point to understand the conformational binding of the mixture as
 518 showed in the **Figure 5**.



519
 520 **Figure 5.** A) Representation of the conformational drug-drug interaction network for the mixture formed
 521 by dicloxacillin and CTAB showing the conformational network architecture resulting from the mixture
 522 with the different binding sites of the ovalbumin (covering from the site $\theta = 1$ to $\theta = 10$). Herein, the
 523 associated colour intensity bar (from blue to red) in the right-side of the network is to represents the strength
 524 of the interactions-based affinity (kcal/mol) of the mixture. Being the x-axis the i-conformation
 525 (dicloxacillin + CTAB) vs. the y-axis as the specific j-binding site evaluated. B) Representation of the best-
 526 ranked binding site of the ovalbumin (site 10, chains C and D) showing the best interaction stability of the
 527 docking complexes coming from the mixture dicloxacillin plus dicloxacillin (network mixed nodes mainly
 528 labelled-mixed orange + green to green + blue colour). C) Representation of the worst-ranked binding site
 529 of the ovalbumin (site 4, chains C and D) showing the worst interaction stability of the docking complexes
 530 for the dicloxacillin plus dicloxacillin system (network mixed nodes mainly labelled mixed blue + grey)
 531 that means lower docking stability for the mixture in the binding site 4.

532 In order to provide an integrated discussion on the mechanistic implications of our
 533 conformational drug-drug interaction network results, we focus solely on the top-ranked
 534 and lowest-ranked binding sites of ovalbumin. This involves considering the stability of
 535 the formed docking complexes with the ligand surfactants acting individually and
 536 forming the mixture in three representative drug-drug binding scenarios: i) OVA +
 537 dicloxacillin, ii) OVA + CTAB, and iii) the mixtures of OVA + dicloxacillin plus CTAB.
 538 In this context, for all the binding scenarios, was theoretically observed that, for the top-
 539 ranked binding sites (**Figure 3B**, **Figure 4B**, and **Figure 5B**), the ligands can interact

540 strongly and simultaneously in the same biophysical environment with the corresponding
541 best-ranked binding sites identified. Specifically, in the case of dicloxacillin drug-drug
542 interactions (see Figure 3B) with the binding site 10 formed between the β -sheets of chain
543 C and the α -helix from chain D. In the case of CTAB, drug-drug interactions occur
544 specifically within binding site 2 formed by two β -loops from a β -sheet and an α -helix
545 that belong to chains A and B, respectively (see **Figure 4B**). On the other hand, in the
546 case of the mixture dicloxacillin plus CTAB, the best-ranked binding site was found in
547 site 10. For this instance, the target pocket is formed by a β -sheet and α -helix from chains
548 C and D, respectively (**Figure 5B**). The theoretical evidence obtained for the best-ranked
549 binding sites strongly suggests that the influence of the mixture (dicloxacillin + CTAB)
550 could have a higher impact than the ligands (dicloxacillin and CTAB) acting separately
551 (please refer to **equation 1**). In this context, from a mechanistic point of view, the
552 occurrence of binding antagonistic mechanisms ($CI > 1$) is more likely than the
553 occurrence of synergistic binding effects ($CI < 1$) due to the different physicochemical
554 nature of the evaluated ligands and the simultaneous interaction of ligands in the same
555 biophysical environment, which could also be modulated by the influence of steric factors
556 under mixture interaction.

557 On the other hand, when analyzing the binding scenario based on the worst-ranked
558 binding sites in the obtained docking complexes with ovalbumin (**Figure 3C**, **Figure 4C**,
559 and **Figure 5C**), we can corroborate that the number of ligand molecules that can bind to
560 these low-affinity sites is significantly lower compared to the best-ranked binding sites
561 cited above. Besides, it is possible to observe that the distribution of ligand molecules is
562 not only restricted to the same biophysical environment as in the previous case (with the
563 best-ranked stability sites for docking), but also the binding distribution was found to be
564 more randomly localized in the ovalbumin binding site structure. This fact suggests that
565 the interaction of individual molecules could occur more likely than the interaction of the
566 mixture (dicloxacillin plus CTAB) for the predicted worst-ranked binding sites (site 4,
567 site 9 involving the chains C and D). In these cases, we could theoretically expect that the
568 combination index (CI) is not affected by the influence of the dicloxacillin + CTAB
569 mixture concentration. However, it could be influenced by the concentration of the
570 ligands acting separately, which is frequently associated with potential synergistic ($CI <$
571 1) or additive effects ($CI = 1$) (please refer to **Figure 2B** above on the combination index
572 CI). Many other relevant factors could affect the biochemical function of ovalbumin in
573 both the unbound and bound states, such as structural perturbations linked to

574 conformational changes that influence the flexibility profile of the ovalbumin protein
575 induced by the ligands and their mixture. Further details can be found in the
576 supplementary information (**Figure S1**).

577 The exploration of the conformational drug-drug interaction network for the entire
578 mixture of dicloxacillin and CTAB is of significant importance in elucidating the
579 antagonist binding obtained above [41-44]. This multimodal approach provides a detailed
580 picture of how the mixture interacts with different binding sites on ovalbumin,
581 showcasing variable stability across these binding sites. Understanding the intricacies of
582 these interactions could shed light on the dynamics of mixture binding. Such theoretical
583 insights not only contribute to our comprehension of the molecular interplay within the
584 mixture but also offer valuable information for the design and optimization of better
585 therapeutic strategies where antagonistic interactions play a crucial role. Therefore, the
586 conformational drug-drug interaction network emerges as a powerful tool for dissecting
587 the complex landscape of antagonist binding in the studied mixture [41-44].


588

589 ***3.2. Experimental validation***

590 ***3.2.1. Absorbance Changes in Ovalbumin Analysis***

591 By leveraging computational simulations, we gain a molecular-level understanding
592 of the interactions within the system, predicting potential binding sites and energy
593 landscapes. These theoretical insights guide our experimental design, providing a
594 roadmap for targeted analyses. Subsequently, experimental findings validate and refine
595 the computational predictions, establishing a reciprocal relationship between theory and
596 practice. To this end, we analyzed absorbance shifts in ovalbumin, which are key to
597 unraveling interaction dynamics. Ovalbumin's UV-Vis absorbance spectrum is
598 intrinsically linked to the presence of its aromatic amino acid residues, primarily
599 tryptophan (Trp) and tyrosine (Tyr), which significantly contribute to its optical
600 properties. Tryptophan, with its complex indole ring structure, is particularly instrumental
601 in determining the protein's spectral behaviour. The indole ring's extensive conjugation
602 allows it to efficiently absorb light in the ultraviolet region, resulting in a dominant
603 absorbance peak at approximately 280 nm, **Figure 6**. This peak is primarily driven by
604 $\pi \rightarrow \pi^*$ electronic transitions within the indole ring. Tyrosine, with its phenolic ring
605 structure, adds to the UV-Vis absorbance spectrum of ovalbumin, typically manifesting
606 with peaks in the range of 270-275 nm. While less intense compared to tryptophan, these
607 tyrosine-associated peaks are nevertheless vital for the overall spectral profile. The

608 absorbance characteristics of these aromatic residues are sensitive to changes in the
609 protein's local environment, including alterations in pH, temperature, or interactions with
610 ligands. Therefore, a comprehensive understanding of ovalbumin's UV-Vis absorbance
611 properties, notably its aromatic amino acid residues, offers a crucial foundation for
612 studying its structural dynamics and the impact of various ligands on the protein's
613 absorbance spectrum. This insight is fundamental to elucidating the structural
614 transformations and binding interactions of ovalbumin and similar proteins in a variety
615 of applications. In the case of dicloxacillin, the UV-Vis absorbance primarily arises from
616 the presence of conjugated functional groups within its molecular structure, with distinct
617 features that reflect its electronic transitions. The absorbance spectrum of dicloxacillin
618 typically displays peaks at specific wavelengths, namely 274 and 280 nm, **Figure 6**,
619 indicative of the presence of chromophoric moieties, including aromatic rings and
620 carbonyl groups. These structural elements are prone to $\pi \rightarrow \pi^*$ and $n \rightarrow \pi^*$ electronic
621 transitions. For its part, the UV-Vis absorbance spectrum of CTAB exhibits main peaks
622 and absorption bands within the 200-300 nm range. Below the Critical Micelle
623 Concentration (CMC), peaks around 205 nm and 215 nm are observed, associated with
624 electronic transitions within individual CTAB molecules. Near the CMC, when CTAB
625 forms micelles, new peaks appear at longer wavelengths (around 250-300 nm), signifying
626 the collective behaviour of CTAB molecules within the micelles. The relationship
627 between concentration and absorbance becomes nonlinear above the CMC, with a
628 saturation effect, signifying the collective behaviour of surfactant molecules within the
629 micelles. This transition often results in a red shift, leading to the emergence of these
630 distinctive absorption peaks. In the present case, the highest value of the ovalbumin 278
631 nm band increases at 298 K upon complexation with the cationic complex until
632 reaching a maximum value (**Figure 6A**, **curve ii.**), then the maximum absorption
633 decreases regularly with increasing concentrations of the ligand mixture, indicating a
634 decrease in hydrophobicity and an increase in polarity [15]. Besides, the red shift
635 observed can be explained by the π - π stacking contact between the aromatic ring of the
636 dicloxacillin molecule and the phenyl rings of amino acid residues, combining charge
637 transfer and hydrophobic forces.



638

639 **Figure 6. A)** Absorbance spectra of OVA ($C_{OVA} = 0.02$ mM) in the absence (unbound OVA) and in the
 640 presence of the mixture of surfactant (Dicloxacillin plus CTAB). **B)** Absorbance spectra of increasing
 641 concentrations of Dicloxacillin. **C)** Absorbance spectra of increasing concentrations of CTAB. $C_{Diclox} =$
 642 C_{CTAB} as 0.08 mM, 0.16 mM, 0.25 mM, 0.33 mM, 0.42 mM, 0.50 mM, 0.58 mM, 0.66 mM, 0.75 mM, 0.83
 643 mM.

644 3.2.2 Assessment of fluorescence features


645 The primary component of the OVA fluorescence spectrum is the Trp fluorescence.
 646 Specifically, OVA contains three Trp residues with distinct structural placements: Trp 160
 647 is exposed to the solvent, Trp 194 is situated within a hydrophobic pocket, and Trp 275 is
 648 partially exposed. When varying amounts of ligands are added, a decrease in OVA
 649 fluorescence occurs within the 290-450 nm range, as depicted in **Figure 7**.

650 The stepwise addition of CTAB to the aqueous solution of the protein initially leads
 651 to a reduction in fluorescence intensity, a trend that persists until a value close to the
 652 critical micellar concentration of CTAB [45]. Subsequently, there is a gradual rise in
 653 fluorescence intensity until it reaches its maximum saturation level. Furthermore, it is
 654 worth noting that CTAB causes a blue shift in the fluorescence spectra once the probe-
 655 micelle interaction reaches saturation. In the lower concentration range of CTAB, the
 656 fluorescence intensity of ovalbumin notably decreases. This phenomenon is a common
 657 occurrence when dealing with lower surfactant concentrations and is often attributed to
 658 the formation of pre-micellar aggregates [45]. This effect is particularly pronounced with
 659 CTAB, given its long chain length [46]. Upon reaching a given concentration near the
 660 CMC, an enhancement in the emission yield becomes evident, indicating a marked

661 departure in the microenvironments enveloping these fluorophores within the CTAB
662 medium in contrast to a pristine aqueous phase, occurrence already demonstrated by [45,
663 47].

664 It is well-documented that water can infiltrate micelles, reaching a certain depth that
665 depends on the compactness of the micellar units [48]. Micelles characterized by more
666 compact headgroups tend to experience less water penetration compared to micelles with
667 less compact headgroups. Neutron scattering experiments conducted on micelles with
668 varying surfactant chain lengths have revealed significant disparities in the headgroup
669 structure of these micelles [48]. This observation strongly implies that as the surfactant
670 chain length increases, the head-group becomes more compact. Consequently, water
671 penetration is relatively minor in CTAB micelles when comparing with other bromide
672 surfactants [45, 48]. Furthermore, the literature also reports an increase in the close
673 packing and microviscosity of alkyltrimethylammonium bromide micelles as the alkyl
674 chain length increases [49]. This leads to the fluorophore experiencing more rigid and
675 less polar environments in CTAB micelles.

676 The observed shift towards the blue end of the spectrum in the fluorescence
677 emissions upon the introduction of CTAB hints at the destabilization of the excited states
678 of these complexes. It also signifies a decrease in the polarity of the micellar solution
679 when compared to the aqueous medium. The fluorescent probe plays a central role in
680 assessing the microscopic polarity of the bio-mimicking environment, utilizing diverse
681 photo-physical parameters to offer a relative measure of the microenvironment's polarity.
682 It's worth emphasizing that the polarities of homogeneous and micro-heterogeneous
683 media cannot be presumed to be identical.



684

685 **Figure 7.** Fluorescence emission spectra obtained from the ovalbumin protein in different binding
 686 conditions as in the absence (Ova unbound state at 0.00 mM) and in the presence of the evaluated ligands
 687 as: **A)** Ova + dicloxacillin, **B)** Ova + CTAB, **C)** Ova + surfactant mixture (dicloxacillin + CTAB) and **D)**
 688 maximum intensity fluorescence vs. surfactant concentrations for the three binding conditions evaluated
 689 (Ova + dicloxacillin, Ova + CTAB, Ova + surfactant mixture). **E)** Results on graph interaction networks of
 690 the fluorescence-sensitive aromatic residues (i.e., phenylalanine Phe, tyrosine Tyr, and tryptophan Trp)
 691 belonging to the ovalbumin target-chains (C and D) regarding the aforementioned binding conditions.
 692 Herein, ovalbumin = 0.02 mM, $C_{\text{Dicloxacillin}} = C_{\text{CTAB}} = (0.083 \text{ mM}, 0.166 \text{ mM}, 0.250 \text{ mM}, 0.330 \text{ mM}, 0.416$
 693 $\text{mM}, 0.500 \text{ mM}, 0.580 \text{ mM}, 0.660 \text{ mM}, 0.750 \text{ mM}, 0.830 \text{ mM})$.


694

To assess the strength of the interaction between i) OVA and dicloxacillin, and ii)
 OVA and the mixture (i.e., CTAB + dicloxacillin), we performed fluorescence quenching
 for the tryptophan amino acid from OVA (OVA-Trp). The emission at 340 nm was
 analyzed using the Stern–Volmer analysis. In the context of the present study, the Stern-
 Volmer plot was used to evaluate the kinetics of the fluorescence deactivation
 (quenching of the OVA-Trp) induced by the ligands as dicloxacillin and the mixture
 CTAB + dicloxacillin (acting as the quenchers in both scenarios). In general, this process
 can be represented by the following simple equation: $P^* + Q \rightarrow P + Q$. Here, P^* represents
 an excited state (denoted by “*”) of the protein OVA-Trp, with fluorescence intensity (F)
 measured in the presence of a given ligand or quencher (Q). The resulting P represents a
 non-excited state of the protein OVA-Trp, with fluorescence intensity (F_0) measured in
 the absence of the quencher Q . The kinetics of this process follow the Stern-Volmer
 relationship, as described in **equation 2**.

707

$$\frac{F_0}{F} = 1 + K_{sv}[Q] \quad (2)$$

708 The parameter K_{sv} represents the Stern-Volmer quenching constant. By plotting the linear
 709 ratio of F_0/F versus the quencher's Q at different concentrations for each system (i.e.,
 710 OVA plus dicloxacillin and OVA plus the mixture of CTAB + dicloxacillin), we can
 711 determine the experimental Stern-Volmer constant.



712

713 **Figure 8.** A) Stern-Volmer plots for the quenching of Ovalbumin by Diclox (○) and the mixture of
 714 surfactants (■). B) Plots of $\log[(F_0-F)/F]$ vs $\log[Q]$ of Diclox (○) and mixture of surfactants (■). $C_{Ovalbumin}$
 715 = 0.02 mM.

716 As shown in the linear Stern-Volmer plot (**Figure 8A**), both ligand systems quench
 717 ovalbumin (OVA) fluorescence, allowing for the determination of the quenching rate
 718 constants and binding affinities. By applying the Stern - Volmer equation, we found that
 719 the quenching constants (K_{sv}) were $7.09 \times 10^2 \text{ mol}^{-1}$ and $33.78 \times 10^2 \text{ mol}^{-1}$ for the OVA
 720 plus dicloxacillin and OVA plus the mixture of CTAB + dicloxacillin); respectively.
 721 Assuming a Trp half-life of the emissive excited state of 10 ns in ovalbumin [50], the
 722 bimolecular quenching constant markedly exceeds the rate of diffusion-limited
 723 quenching, as in water, the maximum value of k_q for diffusion-limited quenching is
 724 approximately $10^{10} \text{ L mol}^{-1} \text{ s}^{-1}$ [51]. Consequently, we could infer the formation of stable
 725 complexes in solution for the evaluated systems by inducing the quenching of OVA
 726 fluorescence through a static mechanism. Next, the static fluorescence quenching
 727 mechanism allowed us to use **equation 3** to experimentally determine relevant binding
 728 parameters such as the Hill cooperativity binding coefficient (n) and the association
 729 constant (K_a) for the aforementioned systems.

730

$$\log \frac{(F_0 - F)}{F} = \log K_a + n \cdot \log [Q] \quad (3)$$

731

732 In the **Figure 8B**, the obtained binding profile as two parallel lines in the plot of log
733 $[(F_0 - F)/F]$ vs. $\log [Q]$ suggests a coherent relationship in the binding behavior of the
734 evaluated systems, dicloxacillin and the CTAB plus dicloxacillin mixture, in terms of
735 interaction with OVA binding sites. Since dicloxacillin is common in both interacting
736 systems, the chemical properties of dicloxacillin may be the main responsible for the
737 observed binding trend. In this regard, this quenching mechanisms (i.e., fluorescence
738 decrease) could be indicative of the presence of potential antagonistic binding
739 mechanisms in two different probable ways as: i) competition for OVA binding sites at
740 the same biophysical environment as showed by the theoretical approaches (refer to
741 **Figure 5B** and **Figure 7C**), ii) coexistence of uncompetitive and competitive inhibition,
742 both of which are antagonistic and non-mutually exclusive mechanisms, involves
743 network conformational changes influencing the binding affinity (refer to **Figure 5A**).
744 Both mechanisms could independently modulate the quenching decrease of OVA
745 interaction. However, additional studies, such as the application of a double reciprocal
746 Lineweaver-Burk plot, could be proposed in future investigations of these hybrid
747 mechanisms [52].

748 Next, The estimated binding parameters (n and K_a) for the aforementioned systems
749 are presented in **Table 1**, following the application of **equation 3**. Regarding the obtained
750 results derived from the **Figure 8B**, the slope (n) of the linear plot of $\log [(F_0 - F)/F]$ vs.
751 $\log [Q]$ provides relevant information on the interaction behavior of the evaluated ligands-
752 based quenchers (i.e., dicloxacillin and the mixture CTAB plus dicloxacillin) with the
753 OVA binding sites. Here, the binding parameter ' n ' corresponds to the experimentally
754 obtained Hill cooperativity coefficient. The experimental parameter ' n ' provides
755 additional insights into the intrinsic dynamics of the OVA with the aforementioned
756 interaction systems. This allows for a better explanation of the cooperativity behavior of
757 binding, which could be associated with potential synergistic, additive, or antagonistic
758 binding effects of the evaluated ligands with the OVA binding sites. Furthermore, there is
759 widespread acknowledgment of the connection between the synergistic, additive, and
760 antagonistic binding mechanisms with the Hill cooperativity binding coefficient (n) [53,
761 54]. From a rigorous mathematical perspective, the following expectations are associated
762 with a mechanistic interpretation of the obtained Hill cooperativity binding coefficient
763 (n) as: i) antagonistic binding manifests when the experimentally observed value of n is
764 strictly < 1 ; ii) synergistic binding occurs when the value of n strictly > 1 , and iii) an
765 additive binding effect is anticipated when the value of n equals 1 [53, 54]. Then, in

766 accordance with the docking results and the theoretical isobologram obtained (Please,
 767 refer to Figure 2B), the antagonistic effects seem to be predominant over synergistic
 768 effects in the concentration range from 0.4 mM to 1 mM.

769 By the other hand, the association binding constant (K_a) can be obtained from the
 770 intercept as $\text{Log } K_a$ [53]. Here, the association constant (K_a) is a crucial parameter that
 771 allows for the measurement of the equilibrium constant for the binding association
 772 between the OVA and the evaluated ligand systems, providing a quantitative kinetic
 773 measure of the strength of the binding interaction. Therefore, a higher K_a value indicates
 774 a stronger binding affinity between the OVA protein and the ligands, such as dicloxacillin
 775 or the mixture of CTAB and dicloxacillin.

776 **Table 1.** Stern-Volmer quenching constants and binding parameters for the interaction of Ovalbumin with
 777 Dicloxacillin and the mixture CTAB plus dicloxacillin at 298 K.

Docking System ID	Stern-Volmer constants		Binding parameters		
	$10^{-2} K_{SV} (\text{mol}^{-1})$	R^2	n	$10^3 K_a (\text{mol}^{-1})$	R^2
OVA plus Diclox	7.09 ± 0.02	0.997	0.908 ± 0.01	3.02 ± 0.04	0.998
OVA plus Mixture	33.78 ± 0.05	0.989	0.913 ± 0.01	15.88 ± 0.01	0.986

778

779 In terms of the association constant, it is worth noting that the value for the mixture
 780 of CTAB + dicloxacillin is approximately 50 times higher than the value for dicloxacillin
 781 interacting alone. These results show that the drug's affinity for the OVA is relatively low
 782 but gets strengthened by the presence of CTAB in the mixture.

783

784 **3.2.3 FRET Insights: Examining Molecular Bonds and Proximity**

785 Energy transfer offers a more comprehensive insight into molecular interactions,
 786 and within the realm of investigating protein-ligand interactions and alterations in protein
 787 structure induced by ligand binding, Fluorescence Energy Transfer (FRET) is of
 788 paramount significance. FRET, firmly rooted in classical physics, operates as a non-
 789 invasive spectroscopic technique, facilitating the non-radioactive transfer of excitation
 790 energy from the protein ovalbumin, which functions as the donor molecule in this context,
 791 to the acceptor molecule(s) in their ground state. Donor molecules, in this scenario,
 792 typically emit photons at shorter wavelengths that significantly overlap with the
 793 absorption spectrum of the acceptor. In this specific case, the shifts observed in the
 794 fluorescence spectra of ovalbumin upon interaction with ligands reveal the occurrence of
 795 energy transfer between the ligands and the protein. Assessing the efficiency of energy
 796 transfer serves as a valuable means for estimating the proximity between the Trp residues

797 within the protein and the ligand. For energy transfer to exist, three essential criteria must
 798 be met: (1) the donor molecule should emit fluorescent light; (2) the absorption spectrum
 799 of the acceptor should exhibit substantial overlap with the fluorescence emission
 800 spectrum of the donor; and (3) the distance separating the donor and acceptor should be
 801 less than 8 - 10 nm [54]. As per Förster's theory, the efficiency of energy transfer (E) can
 802 be mathematically computed using the ensuing expression:

$$E = 1 - (F/F_0) = R_0^6 / (R_0^6 + r^6) \quad (4)$$


803 F represents the fluorescence intensity exhibited by ovalbumin in the presence of
 804 ligands, whereas F₀ signifies the intensity exhibited by the protein in isolation. The
 805 variable 'r' designates the distance at which binding occurs between the donor and the
 806 receptor, and 'R₀' denotes the critical distance for energy transfer. At 'R₀', precisely 50%
 807 of the excitation energy gets transferred to the acceptor. This particular parameter is
 808 ascertainable through the following mathematical expression:

$$R_0^6 = 8.79 \times 10^{-25} K^2 n^{-4} \Phi J \quad (5)$$

809 In this context, K² stands for the spatial orientation factor between the dipoles of
 810 the donor and the acceptor, 'n' signifies the refractive index of the surrounding medium,
 811 Φ represents the fluorescence quantum yield of the donor (in this case, ovalbumin), and
 812 'J' characterizes the spectral overlap between the emission spectrum of the donor and the
 813 absorption spectrum of the acceptor (in this case, dicloxacillin and CTAB). When
 814 determining 'R₀', the factor that introduces the most uncertainty is the dipole orientation
 815 factor, which can potentially vary from 0 to 4. However, in scenarios where both the
 816 protein and the ligands experience rapid tumbling and can assume any orientation, a
 817 commonly accepted value for K² is 2/3. The refractive index 'n' is typically assigned the
 818 value of 1.333, corresponding to the refractive index of water, while Φ is commonly
 819 assumed to be 0.15, aligning with the fluorescence quantum yield of tryptophan. Lastly,
 820 the spectral overlap can be computed as follows:

$$J = \frac{\int_0^\infty F(\lambda) \mathcal{E}(\lambda) \lambda^4 d\lambda}{\int_0^\infty F(\lambda) d\lambda} \quad (6)$$

821 F(λ) is the fluorescence intensity of the protein and E(λ) is the molar absorption
 822 coefficient of the acceptor at a given wavelength λ.



823 **Figure 9.** Overlap area ($J(\lambda)$) of donor fluorescence emission spectrum (blue) and acceptor absorption
 824 spectrum (purple). $T = 298$ K. $C_{OVA} = 0.02$ mM, $C_{Diclox} = C_{CTAB} = 0.50$ mM.
 825

826 Following the explained methodology, **Figure 9** displays the overlap curves
 827 obtained, while **Table 2** provides the corresponding FRET values. Within the cationic
 828 system, the binding distance (denoted as 'r') between the donor and receptor falls in the
 829 range of 2-8 nm. It is noteworthy that the conditions where 0.5 times ' R_0 ' is less than 'r'
 830 and 'r' is less than 1.5 times ' R_0 ' strongly indicate a high likelihood of energy transfer from
 831 ovalbumin to the ligands. This observation aligns with the presence of non-radiative
 832 energy transfer, signifying that the highly excited elements may return to the ground state
 833 [55]. Furthermore, these results provide additional support for the predominant
 834 involvement of static-type fluorescence mechanisms, as previously demonstrated.

835 **Table 2.** Fluorescence resonance energy transfer (FRET) results of the interaction between the
 836 protein Ovalbumin and the mixture of ligands.


Docking System ID	FRET parameters		
	J ($M^{-1} cm^{-1} nm^4$)	R_0 (\AA)	r (nm)
OVA plus Mixture	7.98×10^{12}	18.85	2.59

837

838 **3.2.4 Circular Dichroism (CD) Investigation: Probing Molecular Architecture** 839 **and Structural Characteristics**

840 Far-UV Circular Dichroism is a widely employed technique for discerning the α -
 841 helix and β -sheet secondary structural components in proteins, offering insights into their
 842 conformational variations. In this investigation, the influence of dicloxacillin and the
 843 mixture of surfactants on the secondary structure of ovalbumin was probed through far-
 844 UV CD spectroscopy. The outcomes revealed that the addition of varying concentrations
 845 of dicloxacillin, spanning from 0.083 to 0.33 mM, induced pronounced alterations in the

846 shape of the minima, accompanied by a notable decrease in negative ellipticity. These
 847 changes signify a reduction in the secondary structure of the protein. In a similar way, the
 848 mixture of both surfactants caused an even more pronounced alteration in the CD results
 849 (Figure 10).



850

851 **Figure 10.** Far-UV CD spectra of OVA ($C_{OVA} = 0.02$ mM) with increasing concentrations of: **A)** OVA+
 852 Dicloxacillin ($C_{Diclox} = 0.083$ mM, 0.16 mM, 0.25 mM, 0.33 mM) and **B)** OVA + Mixture ($C_{Diclox} = C_{CTAB}$
 853 = 0.083 mM, 0.16 mM, 0.25 mM, 0.33 mM, 0.45 mM).

854 To quantitatively assess these modifications, the BeStSel analysis was applied to
 855 compute the overall percentage of α -helix structural variations, and the results are
 856 outlined in **Table 3**.

857 **Table 3.** Quantitative results on the contents of ovalbumin α -helices elements (%) as a function
 858 of the surfactant mixture concentration added.

[Surfactant Mixture] (mM)	α – Helix (%)
0.0	38.24
0.083	32.51
0.16	30.98
0.25	28.75
0.33	27.01
0.42	25.13

859

860 As it can be inferred from the results, the mixture of dicloxacillin and CTAB can
 861 significantly influence the results obtained from circular dichroism (CD) spectroscopy
 862 when applied to ovalbumin. The cationic surfactant CTAB can bind to ovalbumin through
 863 electrostatic and hydrophobic interactions, disrupting the protein's native structure.
 864 Additionally, dicloxacillin, can also directly interact with ovalbumin, causing
 865 conformational shifts. These dual interactions may lead to synergistic effects or

866 competing influences on ovalbumin's secondary and tertiary structures, ultimately
867 reflected in the CD spectra. The CD results show variations in the characteristic CD peaks
868 associated with different secondary structural elements, such as α -helices and β -sheets, as
869 well as in the near-UV region where changes in the local environment of aromatic
870 residues are monitored. The chiral environment can also be altered due to these
871 interactions, further impacting the CD spectra. Furthermore, any complex formation
872 between ovalbumin, dicloxacillin, and CTAB will contribute to distinct CD signatures,
873 possibly differing from those of individual components or unbound the protein.
874 Therefore, a mixture of dicloxacillin and CTAB presents a complex interplay of structural
875 modifications within ovalbumin, posing both cooperative and competitive effects that
876 significantly influence the CD results and provide insights into the intricate interactions
877 between the components of the mixture and the protein. It is important to note that
878 mechanistic studies of interactions involving mixture of compounds still pose a
879 significant challenge, and certain experimental limitations are inherent when increasing
880 the complexity of the system under investigation. In this context, strategies for addressing
881 these methodological issues are outlined in the supplementary material (**Table S1**).

882 ***4. Conclusions***

883 Our research has combined computational modelling and experimental methods to
884 enhance our comprehension of the intricate conformational binding between mixtures of
885 dicloxacillin plus CTAB on the ovalbumin protein. This multi-modal network approach
886 has led to significant advancements in our understanding of this subject matter. We
887 identified active sites on ovalbumin and analysed the interaction dynamics, including the
888 possibility of a prevalence of antagonistic binding effects over the synergistic and additive
889 ones by using computational and spectrofluorimetric methods. Our thermodynamic
890 analysis distinguished the isolated binding strengths of CTAB and dicloxacillin, revealing
891 precise insights into their respective interactions with ovalbumin. These computational
892 predictions were experimentally validated by observing changes in ovalbumin's
893 fluorescence properties and confirmed by both, the Stern-Volmer analysis and circular
894 dichroism spectroscopy. The findings fit excellent and confirmed the theoretical models
895 emphasizing that mixture interactions could promote structural and conformational
896 changes in whole ovalbumin and its relevant binding sites. Finally, by combining new
897 computational approaches with experimentally validated spectrofluorimetric data, this
898 work enhances the current understanding on the bio-interactions between proteins and

899 surfactant mixtures. The precise and efficient control over interfacial properties and the
900 conformational behavior of ovalbumin during interaction with the isolated and mixed
901 system could open new opportunities for applications in food processing, chemistry, and
902 the rational design of pharmaceutical drugs.

903

904 **Ethics approval and consent to participate**

905 Not applicable.

906 **Acknowledgements**

907 M.G.D. thanks European Union's H2020 project Sinfonia (N.857253). R.R. and J.M.R.
908 thank Xunta de Galicia for support (ED431B 2022/36). R.R. is granted by the Program for the
909 requalification, international mobility, and attraction of talent in the Spanish university system,
910 modality Margarita Salas (grant UP2021-042).

911

912 **Author Contributions**

913 **Michael González-Durruthy**: Conceptualization, Software, Methodology, Writing
914 – original draft, Writing – review & editing. **Ramón Rial**: Conceptualization, Data
915 curation, Formal analysis, Methodology, Writing – original draft, Writing – review &
916 editing. **Juan M. Ruso**: Supervision, Conceptualization, Writing – review & editing.

- 918 [1] M. Aguirre-Ramírez, H. Silva-Jiménez, I.M. Banat, M.A. Díaz De Rienzo, Surfactants: physicochemical interactions
919 with biological macromolecules, *Biotechnology Letters* 43(3) (2021) 523-535.
- 920 [2] M. Nikbakht Nasrabadi, A. Sedaghat Doost, R. Mezzenga, Modification approaches of plant-based proteins to
921 improve their techno-functionality and use in food products, *Food Hydrocolloids* 118 (2021) 106789.
- 922 [3] J.M. Ruso, N. Deo, P. Somasundaran, Complexation between dodecyl sulfate surfactant and zein protein in solution,
923 *Langmuir* 20(21) (2004) 8988-91.
- 924 [4] J. Maldonado-Valderrama, A. Martín-Molina, A. Martín-Rodríguez, M.A. Cabrerizo-Vílchez, M.J. Gálvez-Ruiz, D.
925 Langevin, Surface Properties and Foam Stability of Protein/Surfactant Mixtures: Theory and Experiment, *The Journal*
926 *of Physical Chemistry C* 111(6) (2007) 2715-2723.
- 927 [5] J. Maldonado-Valderrama, J.M.R. Patino, Interfacial rheology of protein–surfactant mixtures, *Current Opinion in*
928 *Colloid & Interface Science* 15(4) (2010) 271-282.
- 929 [6] R. Miller, V.B. Fainerman, M.E. Leser, M. Michel, Surface tension of mixed non-ionic surfactant/protein solutions:
930 comparison of a simple theoretical model with experiments, *Colloids and Surfaces A: Physicochemical and Engineering*
931 *Aspects* 233(1) (2004) 39-42.
- 932 [7] C. Kotsmar, V. Pradines, V.S. Alahverdijeva, E.V. Aksenenko, V.B. Fainerman, V.I. Kovalchuk, J. Krägel, M.E. Leser, B.A.
933 Noskov, R. Miller, Thermodynamics, adsorption kinetics and rheology of mixed protein–surfactant interfacial layers,
934 *Advances in Colloid and Interface Science* 150(1) (2009) 41-54.
- 935 [8] A. Stenstam, A. Khan, H. Wennerström, Lysozyme in Catanionic Surfactant Mixtures, *Langmuir* 20(18) (2004) 7760-
936 7765.
- 937 [9] J.X. Xiao, U. Sivars, F. Tjerneld, Phase behavior and protein partitioning in aqueous two-phase systems of cationic-
938 -anionic surfactant mixtures, *Journal of chromatography. B, Biomedical sciences and applications* 743(1-2) (2000) 327-
939 38.
- 940 [10] E. Blanco, P. Messina, J.M. Ruso, G. Prieto, F. Sarmiento, Regarding the effect that different
941 hydrocarbon/fluorocarbon surfactant mixtures have on their complexation with HSA, *The journal of physical*
942 *chemistry. B* 110(23) (2006) 11369-76.
- 943 [11] L. Xu, L. Feng, S. Dong, J. Hao, Q. Yu, Carbon nanotubes modified by a paramagnetic cationic surfactant for
944 migration of DNA and proteins, *Colloids and Surfaces A: Physicochemical and Engineering Aspects* 559 (2018) 201-
945 208.
- 946 [12] F. Niu, F. Gu, M. Zhao, Y. Gao, W. Tu, M. Kou, W. Pan, Aggregation and Growth Mechanism of Ovalbumin and
947 Sodium Carboxymethylcellulose Colloidal Particles under Thermal Induction, *Biomacromolecules* 24(3) (2023) 1532-
948 1543.
- 949 [13] S.K. Davidson, D.A. Stahl, Selective recruitment of bacteria during embryogenesis of an earthworm, *The ISME*
950 *Journal* 2(5) (2008) 510-518.
- 951 [14] X. Huang, Z. Tu, H. Wang, Q. Zhang, Y. Shi, H. Xiao, Increase of Ovalbumin Glycation by the Maillard Reaction after
952 Disruption of the Disulfide Bridge Evaluated by Liquid Chromatography and High Resolution Mass Spectrometry,
953 *Journal of Agricultural and Food Chemistry* 61(9) (2013) 2253-2262.
- 954 [15] Y. Zhao, Z. Chen, J. Li, M. Xu, Y. Shao, Y. Tu, Formation mechanism of ovalbumin gel induced by alkali, *Food*
955 *Hydrocolloids* 61 (2016) 390-398.
- 956 [16] F. Niu, Q. Zhang, J. Yu, Y. Huo, L. Zhuo, D. Niu, W. Pan, Interfacial adsorption behavior of ovalbumin/ sodium
957 carboxymethyl cellulose colloidal particles: The effects of preparation methods, *Food Hydrocolloids* 120 (2021)
958 106969.
- 959 [17] P. Taboada, D. Attwood, J.M. Ruso, M. García, F. Sarmiento, V. Mosquera, Influence of Molecular Structure on the
960 Ideality of Mixing in Micelles Formed in Binary Mixtures of Surface-Active Drugs, *Journal of Colloid and Interface*
961 *Science* 216(2) (1999) 270-275.
- 962 [18] P. Severino, M. Szymanski, M. Favaro, A.R. Azzoni, M.V. Chaud, M.H. Santana, A.M. Silva, E.B. Souto, Development
963 and characterization of a cationic lipid nanocarrier as non-viral vector for gene therapy, *European journal of*
964 *pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences* 66 (2015) 78-82.
- 965 [19] S. Ladame, Dynamic combinatorial chemistry: on the road to fulfilling the promise, *Organic & Biomolecular*
966 *Chemistry* 6(2) (2008) 219-226.
- 967 [20] R. Rial, M. González-Durruthy, Z. Liu, J.M. Ruso, Conformational binding mechanism of lysozyme induced by
968 interactions with penicillin antibiotic drugs, *Journal of Molecular Liquids* 358 (2022) 119081.
- 969 [21] Y. Liu, Z. Liu, G. Zeng, M. Chen, Y. Jiang, B. Shao, Z. Li, Y. Liu, Effect of surfactants on the interaction of phenol with
970 laccase: Molecular docking and molecular dynamics simulation studies, *Journal of Hazardous Materials* 357 (2018) 10-
971 18.
- 972 [22] T.C. Chou, Drug combination studies and their synergy quantification using the Chou-Talalay method, *Cancer*
973 *research* 70(2) (2010) 440-6.
- 974 [23] F. Wong, A. Krishnan, E.J. Zheng, H. Stärk, A.L. Manson, A.M. Earl, T. Jaakkola, J.J. Collins, Benchmarking AlphaFold-
975 enabled molecular docking predictions for antibiotic discovery, *Molecular systems biology* 18(9) (2022) e11081.
- 976 [24] D.J. Wooten, C.T. Meyer, A.L.R. Lubbock, V. Quaranta, C.F. Lopez, MuSyC is a consensus framework that unifies
977 multi-drug synergy metrics for combinatorial drug discovery, *Nature Communications* 12(1) (2021) 4607.

978 [25] D.J. Wooten, R. Albert, synergy: a Python library for calculating, analyzing and visualizing drug combination
979 synergy, *Bioinformatics* 37(10) (2020) 1473-1474.

980 [26] A. Ianevski, A.K. Giri, T. Aittokallio, SynergyFinder 2.0: visual analytics of multi-drug combination synergies, *Nucleic
981 Acids Research* 48(W1) (2020) W488-W493.

982 [27] W.P. Feinstein, M. Brylinski, Calculating an optimal box size for ligand docking and virtual screening against
983 experimental and predicted binding pockets, *Journal of Cheminformatics* 7(1) (2015) 18.

984 [28] V. Le Guilloux, P. Schmidtke, P. Tuffery, Fpocket: An open source platform for ligand pocket detection, *BMC
985 Bioinformatics* 10(1) (2009) 168.

986 [29] M.S. Valdés-Tresanco, M.E. Valdés-Tresanco, P.A. Valiente, E. Moreno, AMDock: a versatile graphical tool for
987 assisting molecular docking with Autodock Vina and Autodock4, *Biology Direct* 15(1) (2020) 12.

988 [30] S. Kim, J. Chen, T. Cheng, A. Gindulyte, J. He, S. He, Q. Li, B.A. Shoemaker, P.A. Thiessen, B. Yu, L. Zaslavsky, J.
989 Zhang, E.E. Bolton, PubChem 2023 update, *Nucleic Acids Research* 51(D1) (2022) D1373-D1380.

990 [31] S. Zheng, W. Wang, J. Aldahdooh, A. Malyutina, T. Shadbahr, Z. Tanoli, A. Pessia, J. Tang, SynergyFinder Plus:
991 Toward Better Interpretation and Annotation of Drug Combination Screening Datasets, *Genomics Proteomics
992 Bioinformatics* 20(3) (2022) 587-596.

993 [32] G. Wu, Y. Zheng, H. Zhou, X. Hu, J. Liu, Y. Zhai, M. Zhu, L. Wu, J. Shentu, Safety and pharmacokinetics of dicloxacillin
994 in healthy Chinese volunteers following single and multiple oral doses, *Drug design, development and therapy* 9 (2015)
995 5687-95.

996 [33] N. Li, S. Liu, H. Luo, A NEW METHOD FOR THE DETERMINATION OF THE FIRST AND SECOND CMC IN CTAB
997 SOLUTION BY RESONANCE RAYLEIGH SCATTERING TECHNOLOGY, *Analytical Letters* 35(7) (2002) 1229-1238.

998 [34] S. Preus, DecayFit—Fluorescence Decay Analysis Software 1.3, FluorTools, <http://www.fluortools.com> (2014).

999 [35] A. Micsonai, É. Moussong, F. Wien, E. Boros, H. Vadász, N. Murvai, Y.-H. Lee, T. Molnár, M. Réfrégiers, Y. Goto, Á.
1000 Tantos, J. Kardos, BeStSel: webserver for secondary structure and fold prediction for protein CD spectroscopy, *Nucleic
1001 Acids Research* 50(W1) (2022) W90-W98.

1002 [36] A. Tao, Y. Huang, Y. Shinohara, M.L. Caylor, S. Pashikanti, D. Xu, ezCADD: A rapid 2D/3D visualization-enabled web
1003 modeling environment for democratizing computer-aided drug design, *Journal of chemical information and modeling*
1004 59(1) (2018) 18-24.

1005 [37] P. Buchwald, A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for
1006 Complex Fractional Response Versus Occupancy Data, *Frontiers in pharmacology* 10 (2019) 605.

1007 [38] C.G. Specht, Fractional occupancy of synaptic binding sites and the molecular plasticity of inhibitory synapses,
1008 *Neuropharmacology* 169 (2020) 107493.

1009 [39] J. Corzo, Time, the forgotten dimension of ligand binding teaching, *Biochemistry and molecular biology education*
1010 : a bimonthly publication of the International Union of Biochemistry and Molecular Biology 34(6) (2006) 413-6.

1011 [40] S. Kundu, ReDirection: an R-package to compute the probable dissociation constant for every reaction of a user-
1012 defined biochemical network, *Frontiers in Molecular Biosciences* 10 (2023).

1013 [41] S.I. Berger, R. Iyengar, Network analyses in systems pharmacology, *Bioinformatics* 25(19) (2009) 2466-2472.

1014 [42] M.R. Karim, M. Cochez, J.B. Jares, M. Uddin, O. Beyan, S. Decker, Drug-Drug Interaction Prediction Based on
1015 Knowledge Graph Embeddings and Convolutional-LSTM Network, *Proceedings of the 10th ACM International
1016 Conference on Bioinformatics, Computational Biology and Health Informatics, Association for Computing Machinery,
1017 Niagara Falls, NY, USA, 2019*, pp. 113–123.

1018 [43] K. Han, P. Cao, Y. Wang, F. Xie, J. Ma, M. Yu, J. Wang, Y. Xu, Y. Zhang, J. Wan, A Review of Approaches for Predicting
1019 Drug–Drug Interactions Based on Machine Learning, *Frontiers in pharmacology* 12 (2022).

1020 [44] F. Azuaje, Drug interaction networks: an introduction to translational and clinical applications, *Cardiovascular
1021 Research* 97(4) (2012) 631-641.

1022 [45] A. Mahata, D. Sarkar, D. Bose, D. Ghosh, P. Das, N. Chattopadhyay, Photophysics and rotational relaxation dynamics
1023 of a β -carboline based fluorophore in cationic alkyltrimethylammonium bromide micelles, *Journal of Colloid and
1024 Interface Science* 335(2) (2009) 234-241.

1025 [46] S. Matzinger, D.M. Hussey, M.D. Fayer, Fluorescent Probe Solubilization in the Headgroup and Core Regions of
1026 Micelles: Fluorescence Lifetime and Orientational Relaxation Measurements, *The Journal of Physical Chemistry B*
1027 102(37) (1998) 7216-7224.

1028 [47] S.R. Rai, A. Sarkar, A. Pandey, S. Dasgupta, I. Majumder, D. Das, D. Bose, M. Mukhopadhyay, Photometric Study of
1029 the Interaction of Zinc (II) Complexes of Schiff Bases with Cetyltrimethyl Ammonium Bromide, *Macromolecular
1030 Symposia* 388(1) (2019) 1900030.

1031 [48] S. Berr, R.R.M. Jones, J.S. Johnson, Jr., Effect of counterion on the size and charge of alkyltrimethylammonium
1032 halide micelles as a function of chain length and concentration as determined by small-angle neutron scattering, *The
1033 Journal of Physical Chemistry* 96(13) (1992) 5611-5614.

1034 [49] A.M. Tedeschi, L. Franco, M. Ruzzi, L. Paduano, C. Corvaja, G. D'Errico, Micellar aggregation of
1035 alkyltrimethylammonium bromide surfactants studied by electron paramagnetic resonance of an anionic nitroxide,
1036 *Physical Chemistry Chemical Physics*, 2003, pp. 4204-4209.

1037 [50] J. Ognjenović, M. Stojadinović, M. Milčić, D. Apostolović, J. Vesić, I. Stambolić, M. Atanasković-Marković, M.
1038 Simonović, T.C. Velickovic, Interactions of epigallo-catechin 3-gallate and ovalbumin, the major allergen of egg white,
1039 *Food Chemistry* 164 (2014) 36-43.

1040 [51] E. Gudgin, R. Lopez-Delgado, W.R.J.T.J.o.P.C. Ware, Photophysics of tryptophan in water, deuterium oxide and in
1041 nonaqueous solvents, *The Journal of Physical Chemistry* 87(9) (1983) 1559-1565.
1042 [52] J.-M.G. Rodriguez, N.P. Hux, S.J. Philips, M.H. Towns, Michaelis–Menten Graphs, Lineweaver–Burk Plots, and
1043 Reaction Schemes: Investigating Introductory Biochemistry Students’ Conceptions of Representations in Enzyme
1044 Kinetics, *Journal of Chemical Education* 96(9) (2019) 1833-1845.
1045 [53] J.R. Lakowicz, *Principles of fluorescence spectroscopy*, Springer 2006.
1046 [54] M.D.d.A. Dantas, H.d.A. Tenório, T.I.B. Lopes, H.J.V. Pereira, A.J. Marsaioli, I.M. Figueiredo, J.C.C. Santos,
1047 Interactions of tetracyclines with ovalbumin, the main allergen protein from egg white: Spectroscopic and
1048 electrophoretic studies, *International Journal of Biological Macromolecules* 102 (2017) 505-514.
1049 [55] Y. Liu, Y. Cai, D. Ying, Y. Fu, Y. Xiong, X. Le, Ovalbumin as a carrier to significantly enhance the aqueous solubility
1050 and photostability of curcumin: Interaction and binding mechanism study, *International Journal of Biological*
1051 *Macromolecules* 116 (2018) 893-900.

1052